Oxford Gene Technology Ltd. Release: Complementing NGS Studies With Accurate CNV Detection
10/15/2013 9:52:52 AM
Oxford, UK – 15 October 2013. Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, is inviting delegates of the 63rd Annual Meeting of the American Society of Human Genetics (ASHG) 2013 to attend its workshop and discover the latest strategies for the genomic characterisation of complex disorders. Entitled “Complementing next generation sequencing experiments with high-resolution copy number variation detection”, the workshop will include talks by Professor Madhuri Hegde, Professor of Human Genetics at Emory University School of Medicine and OGT’s Chief Executive, Dr Mike Evans. The workshop will take place at 10:15 on Friday 25 October in the Exhibit Hall.
OGT’s workshop will discuss how microarrays are being used alongside next generation sequencing to deliver accurate detection of point mutations and single exon copy number aberrations. The use of OGT’s CytoSure Molecular Arrays in a CLIA/CAP-certified clinical laboratory will also be covered.
Taking place in Boston (US) on 22-26 October, the ASHG annual meeting is the largest human genetics meeting and exposition in the world, bringing together experts from around the globe to enhance research, teaching and consultation. With the 60th anniversary of the discovery of the double helix and the 10th anniversary of the completion of the Human Genome Project, the theme for this year’s meeting is to celebrate milestones in genetics, and OGT’s workshop complements this theme, exploring where the latest technologies are leading the application of genetics in the future.
Book online to reserve your place at the workshop. Delegates of ASHG can also visit booth #507 to discuss how OGT can assist with microarray and sequencing requirements, and will also have the chance to win an Amazon Kindle Fire tablet.
For more information, please visit www.ogt.com.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: firstname.lastname@example.org
W: www.ogt.com ; Twitter: @OxfordGeneTech
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Help employers find you! Check out all the jobs and post your resume.
comments powered by